Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16019499 | 0.90 | HTR2A (0.36) | HTR2AHTR2CHTR2B | |
| SCHEMBL18949698 | 0.79 | ACHE (0.42) | ACHEHTR2AHTR2CHTR2B | |
| SCHEMBL23771343 | 0.77 | ACHE (0.38) | ACHE | |
| SCHEMBL16019500 | 0.75 | APLNR (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL16019537 | 0.74 | BUB1 (0.33) | — | |
| SCHEMBL30666497 | 0.74 | ACHE (0.44) | ACHEHTR2AHTR2CHTR2B | |
| SCHEMBL20897989 | 0.74 | ACHE (0.41) | ACHE | |
| SCHEMBL21893441 | 0.73 | ACHE (0.38) | ACHE | |
| SCHEMBL27011101 | 0.72 | HTR2A (0.32) | HTR2AHTR2CHTR2B | |
| SCHEMBL13524885 | 0.72 | HTR2A (0.38) | ACHEHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20180079759-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2018-03-22 | — | — | US | disclosed |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-05 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| US-9512148-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2015-11-12 | — | — | US | disclosed |
| US-9127024-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION | 2014-09-18 | — | — | US | disclosed |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | ACHE 4101/4885HTR2A 3062/4885HTR2C 4045/4885 |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | ACHE 4101/4885HTR2A 3062/4885HTR2C 4045/4885 |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | ACHE 4615/4885HTR2A 4199/4885HTR2C 4249/4885 |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | ACHE 2175/4885HTR2A 3896/4885HTR2C 4650/4885 |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | ACHE 4615/4885HTR2A 4199/4885HTR2C 4249/4885 |
| US-20180079759-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | ACHE 4101/4885HTR2A 3062/4885HTR2C 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.